Personalized Search
Displaying 1 - 20 of 175
Saturday, October 24, 2026Conference Co-ChairsUma Borate, MBBSAlice Mims, MDAplastic Anemia/PNH Agenda 7:30 - 8:15 Breakfast and Registration8:15 - 8:45 Welcome 8:45 - 9:15
Bone Marrow Failure
Bone Marrow Failure:
A condition that occurs when the bone marrow stops making enough healthy blood cells. The most common of these rare diseases are…
Conference Event last updated
.
HighlightsReduced cumulative post-transplant
cyclophosphamide
cyclophosphamide:
Cyclophosphamide is in a class of medications called alkylating agents. When used to treat cancer, it works by slowing or stopping the growth of cancer cells in your body. When cyclophosphamide is used to treat bone marrow failure, it works by suppressing your body's immune system.
(<…
Article last updated
.
Key PointsPosttransplant
cyclophosphamide
cyclophosphamide:
Cyclophosphamide is in a class of medications called alkylating agents. When used to treat cancer, it works by slowing or stopping the growth of cancer cells in your body. When cyclophosphamide is used to treat bone marrow failure, it works by suppressing your body's immune system.
significantly reduced GVHD…
Article last updated
.
ABSTRACTIntroductionCentral venous catheter (CVC) insertion is frequently required in patients with haematological diseases. Despite limited evidence,
thrombocytopenia
thrombocytopenia:
(throm-buh-sie-tuh-PEE-nee-uh) A condition in which there is a shortage of platelets in the bloodstream. This results in a low platelet count. Bleeding and bruising…
Article last updated
.
IntroductionPayers employ health care utilization–management strategies, including prior authorization (PA), to limit costs and promote evidence-based, guideline-concordant care. However, PA may be inconsistently applied and associated with patient confusion and frustration.1-3 Patient engagement in PA processes can add to administrative burden and may be associated with adverse…
Article last updated
.
CONFERENCE AGENDA - November 7, 20268:00 - 2:45 (Central Time Zone)
Aplastic Anemia
Aplastic Anemia:
(ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood cells, white blood cells, and platelets. The term aplastic is a Greek word meaning not to form. Anemia is a condition that happens when red blood cell count is…
Conference Event last updated
.
Highlights•There are no differences in NRM in patients receiving prior CAR T versus no CAR T.•There are no differences in GVHD in patients receiving prior CAR T versus no CAR T.•HCT within 3 months of CAR T had less grades III to IV acute GVHD.ABSTRACTIt remains unclear whether prior chimeric antigen receptor (CAR) T-cell therapy is associated with an increased risk of
graft-versus-host…
Article last updated
.
CONFERENCE LOCATION:Heldrich Hotel 10 Livingston AvenueNew Brunswick, NJ 08901Parking: Complimentary hotel valet parking CONFERENCE AGENDA
Aplastic Anemia
Aplastic Anemia:
(ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood cells, white blood cells, and platelets. The term aplastic is a Greek…
Conference Event last updated
.
Key PointsBCL2 overexpression in T cells is related to a lower risk of GVHD.BCL2 inhibitors should be used with caution after allogeneic hematopoietic stem cell transplantation.Abstract
Graft-versus-host disease (GVHD)
Graft-versus-host disease (GVHD):
Also called GVHD, it is a common complication of bone marrow/stem cell transplantation. It is caused when the donor's immune cells, now…
Article last updated
.
Highlights
While post-transplantation
cyclophosphamide
cyclophosphamide:
Cyclophosphamide is in a class of medications called alkylating agents. When used to treat cancer, it works by slowing or stopping the growth of cancer cells in your body. When cyclophosphamide is used to treat bone marrow failure, it works by suppressing your body's immune system.
(PTCy) was compared to other…
Article last updated
.
Abstract
Expression levels of
HLA
HLA:
See human leukocyte antigen.
are associated with susceptibility to various diseases and outcomes after allogeneic hematopoietic cell transplantation (HCT). However, there has been no comprehensive analysis of the effect of the expression levels of the HLA-A, -B, -C, and -DRB1 alleles in unrelated HCT (UR-HCT). Using the capture RNA-sequencing…
Article last updated
.
Session Recordings Available:
Conference Event last updated
.
Recorded Sessions:
Conference Event last updated
.
Here are links to the conference sessions from the 2025 Kansas City Patient and Family Conference:
Conference Event last updated
.
DEADLINE MAY 8Senators Roger Wicker (R-MS) and Dick Durbin (D-IL) are circulating a bipartisan letter to the Senate in support of increased funding for the Department of Defense’s medical research accounts, including CDMRP and BMFRP.You can help by asking Your Senators to Sign the LetterSenators Roger Wicker (R-MS) and Dick Durbin (D-IL) are circulating a…
Article last updated
.
Abstract
Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (HCT) is essential for treatment planning; however, the parameters that define an “optimal” donor in the modern era are not well defined. Historically, donor-recipient
HLA
HLA:
See human leukocyte antigen.
mismatching correlated strongly with risk for
graft-versus-host…
Article last updated
.
ABSTRACT
Regimens combining calcineurin inhibitors with methotrexate or mycophenolate have been the backbone for
graft-versus-host disease (GVHD)
graft-versus-host disease (GVHD):
Also called GVHD, it is a common complication of bone marrow/stem cell transplantation. It is caused when the donor's immune cells, now in the patient, begin to see the the patient's body as foreign and mount…
Article last updated
.